Key result
Anti-CCP antibodies in rheumatoid arthritis linked to ischemic heart disease and higher mortality.
Why the study?
Does the presence of anti-CCP antibodies predict the development of ischemic heart disease and mortality in patients with rheumatoid arthritis?
Population
937 patients with rheumatoid arthritis (RA)
Design
Cohort
Authors
Loading...
May identify RA patients for intensified CV monitoring; hypothesis-generating and should not yet alter practice.
Cohort (n=937)
Does the presence of anti-CCP antibodies predict the development of ischemic heart disease and mortality in patients with rheumatoid arthritis?
In patients with rheumatoid arthritis, the presence of anti-CCP antibodies is an independent risk factor for ischemic heart disease and increased mortality.
López‐Longo et al. (2009) conducted a cohort in Rheumatoid arthritis (n=937). Anti-cyclic citrullinated peptide (anti-CCP) antibodies vs. Absence of anti-CCP antibodies was evaluated on Development of ischemic heart disease and other clinical correlates. The presence of anti-CCP antibodies in patients with rheumatoid arthritis was independently associated with the development of ischemic heart disease, worse joint involvement, and higher mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: